Ogalvibart

Names

[ CAS No. ]:
2599039-60-6

[ Name ]:
Ogalvibart

Biological Activity

[Description]:

Ogalvibart (C-135-LS) is a humanized anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model[1].

[Related Catalog]:

Research Areas >> Infection
Signaling Pathways >> Anti-infection >> SARS-CoV

[Target]

SARS-CoV-2[1].


[In Vivo]

Ogalvibart (C-135-LS; 10 mg/kg; 感染前 75 天给药) 联合 10 mg/kg 的 C144LS 时，能有效阻断恒河猴疾病模型中 COVID19 的发展[1]。 Animal Model: Rhesus macaques (3-11 years old)[1]. Dosage: 10 mg/kg (in combination with 10 mg.kg C144LS) Administration: 75 days before infection Result: Protected a subset of animals whose infectious challenge was 75 days post administration from disease.

[References]

[1]. Beddingfield BJ, et al. Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies. Front Cell Infect Microbiol. 2021 Nov 18;11:753444.  

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.